The head of the COVID-19 Vaccine Task Force said on Tuesday that the Pfizer vaccine could be available to Australians under the age of 40 as early as September or October.
Lieutenant John Fluen told reporters that the amount of Pfizer vaccine imported is currently limited and that locally produced AstraZeneca is plentiful. Therefore, the priority of the current age group remains unchanged.
Currently, most people under the age of 40 are not qualified for Pfizer, but you can consider taking AstraZeneca after consulting your GP.
However, once the Moderna mRNA vaccine is approved and a sufficient supply of Pfizer is available, Frewen said more options will be available.
“But at this stage you are not tied to a particular date.” He told the media..
Federal and state health authorities met today to discuss future national expansion plans.
With tens of millions of Pfizer and Modana doses arriving later this year, there are concerns surrounding a shortage of staff to administer the vaccine.
“The ability to deliver an ever-growing number of vaccines towards the end of the year is a challenge,” says Frewen. “We have already predicted that labor problems may occur in some states and territories, especially in some smaller jurisdictions.”
Options to meet personnel requirements with trainee emergency medical personnel and final grade medical students are also currently under consideration. In addition, the possibility of improving some of the current workforce is also being considered.
“All these types of options are in the table.” Frewen said ABC. “We are looking for every opportunity we can to accelerate our deployment.”
Frewen will also meet with Treasury Josh Frydenberg and other industry leaders in an online forum tomorrow to discuss how to incorporate the industry into the plan.
Leaders will also discuss the option of launching a workplace immunization program as another option to accelerate deployment. It also helps reduce pressure from the primary health care system.
“Many of these industries are already vaccinated against the flu every year,” says Frewen. “So I think COVID also has some appeal in its ability to vaccinate in the workplace.”
“They are accustomed to vaccination of their workforce, which is potentially another efficiency of the program.”